Exclusive Content
ViiV Healthcare Advances HIV Care with Breakthrough Long-Acting Injectable Data at AIDS 2026
ViiV Healthcare, the global specialist HIV company majority-owned by GSK plc, announced landmark clinical, real-world, and pipeline data presented at the 26th International AIDS...
Wockhardt Launches “Wockhardt Antibiotic Academy” to Tackle Growing Threat of Multidrug Resistance in India
Wockhardt Limited announced the launch of the Wockhardt Antibiotic Academy, a national initiative dedicated to fostering patient-centric scientific dialogue and advancing continuous medical education to...
Optimus Pharma Secures Regulatory Approval for Non-Steroidal Tapinarof Cream to Treat Plaque Psoriasis
Optimus Pharma, a leading Indian pharmaceutical manufacturer and subsidiary of Sekhmet Pharmaventures, announced that it has received regulatory marketing approval for Tapinarof cream, an...
Enhertu Shows Better Results Than Standard Treatment in Lung Cancer Trial
AstraZeneca and Daiichi Sankyo announced that their antibody-drug conjugate Enhertu (trastuzumabderuxtecan) has achieved a statistically significant and clinically meaningful improvement in progression-free survival in the Phase...
AstraZeneca Halts Phase III eVOLVE-Lung02 Trial of Volrustomig in Advanced Lung Cancer
AstraZeneca has announced it is stopping its Phase III eVOLVE-Lung02 study, which was testing volrustomig combined with chemotherapy as a first-line treatment for metastatic non-small cell...
Argenx’s Efgartigimod Clears Phase 3, Bringing New Hope for Autoimmune Myositis
argenx SE (Euronext & Nasdaq: ARGX) reported on August 17 that its Phase 3 ALKIVIA trial of subcutaneous efgartigimod (marketed as VYVGART Hytrulo) achieved its primary goal in...
